


Brilliant Violet 421™ anti-mouse CD326 (Ep-CAM)

Catalog # / Size: 1191125 / 50 µg
Clone: G8.8
Isotype: Rat IgG2a, κ
Immunogen: TE-71 thymic epithelial cell line
Reactivity: Mouse
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Concentration: 0.2



TE-71 (mouse thymic epithelial stromal cell line) was stained with CD326 (clone G8.8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Additional reported applications for clone G8.8 (for the relevant formats) include: immunohistochemistry of frozen sections: acetone fixed¹, with or without OCT embedding^{2,4}.

- Application References:**
1. Farr A, *et al.* 1991. *J. Histochem. Cytochem.* 39:645. (FC, IHC)
 2. Dooley J, *et al.* 2005. *J. Immunol.* 175:4331. (FC, IHC)
 3. Hinterberger M, *et al.* 2010. *Nat. Immunol.* 11:512. (FC) [PubMed](#)
 4. Gracz AD, *et al.* 2010. *Am J. Physiol Gastrointest Liver Physiol.* 298:590. (IHC) [PubMed](#)
 5. Nudel I, *et al.* 2011. *J. Immunol.* 186:891. [PubMed](#)
 6. Morimoto H, *et al.* 2012. *Biol Reprod.* 86:148. [PubMed](#)
 7. Ishii K, *et al.* 2012. *Development.* 139:1734. [PubMed](#)
 8. Takehashi M, *et al.* 2012. *Biol Reprod.* 86:178. [PubMed](#)

9. Murakami R, *et al.* 2013. *PLoS One*. 8:73270. [PubMed](#)
 10. Taguchi K, *et al.* 2014. *Mol Cell Biol*. 34:900. [PubMed](#)
 11. Hirokawa Y, *et al.* 2014. *Am J Physiol Gastrointest Liver Physiol*. 306:547. [PubMed](#)
 12. Ding X, *et al.* 2015. *Cancer Res*. 75:330. [PubMed](#)
-

Description: EpCAM (CD326) mediates calcium-independent homophilic cell to cell adhesion. It may also function as a growth factor receptor. It is thought to be involved in maintaining cells in position during proliferation. Expression of EpCAM seems to correlate inversely with the level of E-cadherin (CD324). EpCAM is considered important in tumor biology.

- Antigen**
- References:**
1. Borkowski TA, *et al.* 1996. *Eur. J. Immunol*. 26:110.
 2. Bergsagel PL, *et al.* 1992. *J. Immunol*. 148:590.